NARA Discovery
NARA Subscribed Scholarly Literature Discovery
Boolean search: climate AND coral · microplastic OR nanoplastic · plastic NOT freshwater · "marine heatwave"
Advanced Search
Topic searches article titles and abstracts. Starts a new search; publisher and year refine it.
Searches article titles and abstracts.
Accepts bare DOI, doi: prefix, or a doi.org URL.
Complete publisher name. Publisher imprints are grouped under their main publisher where applicable.
Exact match by full journal title or ISSN.
–
Refine Results Clear Filters
Collection
NARA Subscribed2
Publisher
Springer Nature2
Journal
Pharmaceutical Research2
Publication Year
20211
20201
Peter Stopfer results 2 · Newest (Page 1/1, per page 25)
Export CSV Export RIS Export current results · up to 5,000 records
Author: Peter Stopfer ×Clear All Filters
Search Results
Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug InteractionsNARA Subscribed
Pharmaceutical Research · 2021 · Vol. 38 · Issue 10 · Springer
Nina Hanke; José David Gómez-Mantilla; Naoki Ishiguro; Peter Stopfer; Valerie Nock
Purpose To build a physiologically based pharmacokinetic (PBPK) model of the clinical OATP1B1/OATP1B3/BCRP victim drug rosuvastatin for the investigation and prediction of its transporter-mediated drug-drug interactions (DDIs). Methods The Rosuvastatin model was developed using the open-source PBPK software PK-Sim®, following a middle-out approach. 42 clinical studies (dosing range 0.002–80.0 mg), providing rosuvastatin plasma...
View Details View Full Text
Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug InteractionsNARA Subscribed
Pharmaceutical Research · 2020 · Vol. 37 · Issue 12 · Springer
Hannah Britz; Nina Hanke; Mitchell E. Taub; Ting Wang; Bhagwat Prasad; Éric Fernandez; Peter Stopfer; Valerie Nock; Thorsten Lehr
Purpose To provide whole-body physiologically based pharmacokinetic (PBPK) models of the potent clinical organic anion transporter (OAT) inhibitor probenecid and the clinical OAT victim drug furosemide for their application in transporter-based drug-drug interaction (DDI) modeling. Methods PBPK models of probenecid and furosemide were developed in PK-Sim®. Drug-dependent parameters and plasma concentration-time profiles follow...
View Details View Full Text